Clinical Trial Pharmacy Supply Checklist

When a clinical trial site’s research pharmacy — its investigational drug service (IDS) — receives investigational product, receiving and storing it correctly is only the first half of the job. Before a dose reaches a subject, pharmacy staff still have to prepare it: reconstitute or dilute it, compound it under sterile or hazardous-drug conditions if the formulation calls for that, preserve blinding, and document every step in a way that survives sponsor monitoring. This checklist covers what an IDS needs to stock to get investigational product from the pharmacy shelf into administrable form — the compounding, aseptic-technique, blinding-preservation, and documentation supplies specific to a research pharmacy. It is the pharmacy-specific companion to the Clinical Trial Site Startup Supply Checklist, which covers general clinical consumables; this guide picks up where that one deliberately stops.

Where to source this: Sterile IV admixture and reconstitution work in a research pharmacy draws on the same general-purpose sterile fluid and disinfection stock any pharmacy compounding area uses — it isn’t sponsor-supplied. CASRAI’s sister medical-supply company, LAC (lac.us), carries this stock: browse its IV Bags category for diluent and admixture bags, and its Alcohol Prep Pads category for the vial-top and port disinfection every USP <797> aseptic technique step requires, if a pharmacy is sourcing this stock outside an existing GPO or wholesaler contract.

The Two Streams This Checklist Sits Between

A research pharmacy is really managing three distinct things at once, and this checklist covers only the middle one:

• The investigational product itself — sponsor-controlled, GMP-manufactured, tracked through IRT/IWRS, received and accounted for under the sponsor’s own chain-of-custody requirements. See Clinical Trial Supply Management for that side in full: manufacturing, distribution, and accountability.
• Preparing the IP for dosing — reconstitution, compounding, blinding-preserving repackaging, and the aseptic-technique and documentation supplies that support it. This is what this checklist covers.
• Running the IDS as a function — staffing, SOPs, delegation-of-authority scope for pharmacy roles, and the regulatory relationship between the pharmacy and the rest of the site. See Investigational Drug Service (IDS) and Research Pharmacy: How Sites Set Up, Staff, and Run an Investigational Drug Service for that operational layer, and Research Pharmacy SOP for how the documentation this checklist references gets structured into an actual procedure.

Conflating these three is the same mistake the site-startup checklist warns against at the general-clinical level, just one layer deeper: a preparation-supply decision (which diluent, which overwrap) is not sponsor-controlled the way the IP itself is, but it still has to match what the protocol’s pharmacy manual specifies for that study, and it still has to preserve whatever blinding the protocol requires.

Sterile Compounding Supplies for IP Preparation

Most investigational products that require reconstitution, dilution, or admixture before dosing fall under USP General Chapter <797> (“Pharmaceutical Compounding — Sterile Preparations”), the same chapter that governs sterile compounding in any hospital or specialty pharmacy. What that means for stocking:

• Primary engineering control (PEC) — an ISO Class 5 laminar airflow workbench or biosafety cabinet, sized and certified for the compounding volume the study generates. This is facility infrastructure, not a per-study consumable, but it gates everything else on this list: nothing here should be prepared on an open bench.
• Sterile diluents and admixture bags — the specific diluent and volume are protocol-specified, but the pharmacy still needs general-purpose sterile IV bags on hand for reconstitution and admixture work that isn’t itself the sponsor-supplied IP.
• Needleless connectors, transfer sets, and syringes — sized to the preparation volumes the protocol’s pharmacy manual specifies, in low-retention/low-sorbing formulations where the IP’s stability data calls for it.
• 70% isopropyl alcohol prep pads — USP <797> aseptic technique requires disinfecting vial stoppers, ampule necks, and injection ports immediately before each puncture or connection, every time, not once per compounding session. This is the single highest-volume consumable in a compounding area precisely because the requirement is per-entry, not per-batch.
• Sterile gloves and gowning supplies — garbed and gloved per the PEC’s certification requirements, with glove changes on any breach of sterile technique.

Hazardous-Drug Handling and Containment

Many investigational oncology and biologic agents are NIOSH-listed hazardous drugs, which pulls compounding into USP General Chapter <800> (“Hazardous Drugs — Handling in Healthcare Settings”) on top of <797>. See USP 800 Cleanroom Requirements for the facility side (negative-pressure buffer rooms, external venting, ISO classification); the consumables layer on top of that facility investment includes:

• Closed-system transfer devices (CSTDs) — required by many sponsors’ pharmacy manuals for hazardous IP regardless of what USP <800> strictly mandates for that specific drug, since CSTD use is increasingly the sponsor’s own risk-management position, not just a regulatory floor.
• Chemotherapy-rated gowns and double gloving — ASTM-rated for hazardous drug handling, distinct from standard compounding gowns.
• Spill kits rated for the specific hazard class — staged inside the compounding area itself, not just in a central pharmacy location, since a spill during IP preparation has to be contained without breaching the sterile field for anything not affected.
• Segregated hazardous-waste containers — for trace-contaminated preparation waste, kept separate from the general sharps and pharmaceutical waste streams.

Blinding-Preserving Preparation Supplies

In a blinded study, the preparation step is where blinding most often breaks if the pharmacy isn’t stocked to preserve it. At a general level — the specific blinding scheme is always protocol-defined, and pharmacy staff should follow the protocol’s unblinding-role assignments exactly rather than improvise around a supply gap:

• Opaque overwrap bags or sleeves for prepared IV bags and syringes, sized to fully conceal any visual difference between active and comparator/placebo preparations (color, particulate, fill volume).
• Blinded labeling stock — pre-printed or pharmacy-generated labels that carry only the subject/kit identifier the protocol specifies, never the drug name or arm assignment, applied by the unblinded preparer before the product leaves the compounding area.
• Matching administration sets for active and comparator arms, so tubing, filter type, or infusion rate can’t itself unblind the administering nurse.
• A physically separated unblinded-preparer workspace where the protocol requires one, with its own access log distinct from the general compounding area’s.

For products carrying a Risk Evaluation and Mitigation Strategy, see REMS: When One Is Required for how REMS-specific dispensing restrictions layer on top of ordinary blinded-dispensing controls. For how unblinding actually happens when it’s medically necessary mid-study, see DMC Charter and Unblinding Procedures.

Temperature-Controlled Storage and Monitoring

Once IP is prepared, most formulations have a defined beyond-use time that depends on maintaining a specific storage temperature until administration — a compounding-adjacent stocking need, not a facility one:

• Pharmacy-grade refrigerators and freezers with continuous digital monitoring, not a household unit with a dial thermometer — sponsor pharmacy manuals and FDA inspectors both expect a continuous, auditable temperature record, not a twice-daily manual log.
• Backup power or a documented excursion-response plan for the compounding-storage unit specifically, separate from whatever backup covers general IP receipt-and-storage refrigeration.
• Insulated transport containers with data loggers for moving a prepared dose from the pharmacy to the point of administration when that transit crosses a temperature-sensitive window.

See Temperature Excursion for what counts as one and how to respond, and Pharma Cold Chain Logistics for the broader temperature-band and GDP framework this sits inside.

Drug Accountability and Documentation Supplies

Every step above generates a paper or electronic record a monitor will ask to see. Stocking the documentation infrastructure is as real a checklist item as stocking the alcohol pads:

• Drug accountability logs — per-preparation records of what was compounded, from which lot, in what quantity, by whom, witnessed by whom (double-check/independent-verification requirements are common for hazardous or high-risk preparations).
• Preparation worksheets that capture the calculation used for dose/volume, independently checked before dispensing — this is the record that catches a math error before it reaches a subject.
• Return-and-destruction documentation for unused or expired prepared product, reconciled against the accountability log at study close-out.
• Locked, access-logged storage for controlled-substance IP specifically, meeting DEA storage requirements on top of the sponsor’s own security expectations.

See Research Pharmacy SOP for how to structure these into an actual written procedure rather than a loose collection of forms.

Frequently Asked Questions

Does every research pharmacy need a full USP <800> negative-pressure compounding room?

Only if the specific investigational product is a NIOSH-listed hazardous drug requiring sterile compounding. Non-hazardous sterile preparations still need a USP <797> primary engineering control, but not the negative-pressure buffer room, external venting, and ISO-classified anteroom that <800> adds on top for hazardous sterile compounding. Check the specific IP’s hazard classification and the protocol’s pharmacy manual rather than assuming either standard applies by default.

How is this different from the site startup supply checklist?

The site startup checklist covers general clinical consumables the whole site stocks regardless of protocol — PPE, IV/phlebotomy supplies, wound care, emergency response. This checklist is specific to the pharmacy’s own preparation work on investigational product itself: compounding, blinding preservation, and the documentation that supports it. A site typically needs both.

Who should have access to blinded investigational product during preparation?

Only staff assigned an unblinded role under the protocol’s delegation-of-authority log, and only for the specific tasks that role covers. This is a protocol-defined assignment, not a pharmacy stocking decision — the supply-side answer is making sure the physical workspace and labeling stock actually support keeping that separation real, not just documented.

Do placebo and comparator preparations need the same handling as active IP?

Generally yes for accountability and blinding purposes — a placebo or comparator is still protocol-controlled supply and still needs to be indistinguishable in preparation and presentation from the active arm. Hazardous-handling requirements (USP <800> controls, CSTDs) apply based on the pharmacologic hazard of what’s actually in the syringe or bag, which for an inert placebo is often less stringent than for the active drug — confirm against the specific product’s hazard classification rather than assuming parity across every requirement.

A research pharmacy that has both this checklist and the general site-startup checklist covered has closed the two supply gaps that most often surface at a monitoring visit: consumables that were never protocol-specified but were still expected to be there, and preparation documentation that exists but doesn’t actually reconstruct what happened at the bench.